PEG-Interferon alfa 2a

DRUG2 trials

Sponsors

Bristol-Myers Squibb, Third Affiliated Hospital, Sun Yat-Sen University

Conditions

Hepatitis BHepatitis C, Genotype 1Liver Fibrosis

Phase 3

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

CompletedNCT01471574

Bristol-Myers SquibbHepatitis C, Genotype 1

Start: 2011-12-31End: 2014-09-30Updated: 2016-01-29

Unknown Phase

Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis

Third Affiliated Hospital, Sun Yat-Sen UniversityHepatitis B, Liver Fibrosis

Start: 2019-11-06End: 2023-07-30Target: 186Updated: 2020-01-22

Related Papers

Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.

2017-02-161 citations